Literature DB >> 34524554

Approach to Resectable Biliary Cancers.

Kimberly Washington1, Flavio Rocha2.   

Abstract

OPINION STATEMENT: Biliary malignancies, although rare, can be some of the most challenging to manage surgically. Intrahepatic cholangiocarcinomas are resectable if there is no evidence of metastatic disease. These tumors are managed with anatomic resection and portal lymphadenectomy when centrally located or multiple in a single lobe. Non-anatomic resection can be performed for solitary peripheral tumors with minimally invasive techniques. It is not our practice to routinely employ neoadjuvant chemotherapy prior to resection of these tumors. Hepatic arterial infusion chemotherapy is utilized at our institution in highly selected patients in the context of an ongoing clinical trial for unresectable tumors. Hilar cholangiocarcinomas, when resectable (i.e., ipsilateral arterial involvement or lack of vascular involvement), are managed with right or left (extended) hepatectomy, caudate resection, and portal lymphadenectomy. Distal cholangiocarcinomas are managed with pancreaticoduodenectomy. Neoadjuvant chemotherapy is not routinely used in our treatment algorithm of extrahepatic cholangiocarcinomas. Nodal involvement and positive margin (R1) resection necessitates adjuvant chemotherapy. Finally, gallbladder carcinoma is managed with radical cholecystectomy, anatomic segment IVb/V resection, and portal lymphadenectomy. Adjuvant chemotherapy is employed routinely amongst patients with T2 or higher tumors and those with positive lymph nodes.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cholangiocarcinoma; Extrahepatic cholangiocarcinoma; Gallbladder cancer; Hilar cholangiocarcinoma; Intrahepatic cholangiocarcinoma

Mesh:

Year:  2021        PMID: 34524554     DOI: 10.1007/s11864-021-00896-3

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  40 in total

1.  The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium.

Authors:  Neal Bhutiani; Charles R Scoggins; Kelly M McMasters; Cecilia G Ethun; George A Poultsides; Timothy M Pawlik; Sharon M Weber; Carl R Schmidt; Ryan C Fields; Kamran Idrees; Ioannis Hatzaras; Perry Shen; Shishir K Maithel; Robert C G Martin
Journal:  Surgery       Date:  2018-01-03       Impact factor: 3.982

2.  ASO Author Reflection: Trends and Impact of Adjuvant Chemotherapy in Resected Gallbladder Cancer: Going Beyond Trial Data.

Authors:  Phillip M Kemp Bohan; Daniel W Nelson
Journal:  Ann Surg Oncol       Date:  2020-08-05       Impact factor: 5.344

3.  Repeated resection for recurrent intrahepatic cholangiocarcinoma: A retrospective German multicentre study.

Authors:  Fabian Bartsch; Johannes Eberhard; Felix Rückert; Moritz Schmelzle; Nadja Lehwald-Tywuschik; Stefan Fichtner-Feigl; Jochen Gaedcke; Karl J Oldhafer; Felix Oldhafer; Markus Diener; Arianeb Mehrabi; Utz Settmacher; Thomas Becker; Tobias Keck; Helmut Friess; Benjamin Strücker; Sabine Opitz; Johannes Lemke; Andreas Schnitzbauer; Hauke Lang
Journal:  Liver Int       Date:  2021-01       Impact factor: 5.828

4.  Prognostic Impact of Paraaortic Lymph Node Metastasis in Extrahepatic Cholangiocarcinoma.

Authors:  Nobuhito Nitta; Katsuhisa Ohgi; Teiichi Sugiura; Yukiyasu Okamura; Takaaki Ito; Yusuke Yamamoto; Ryo Ashida; Shimpei Otsuka; Keiko Sasaki; Katsuhiko Uesaka
Journal:  World J Surg       Date:  2020-10-20       Impact factor: 3.352

Review 5.  Surgical Considerations of Hilar Cholangiocarcinoma.

Authors:  Blaire Anderson; M B Majella Doyle
Journal:  Surg Oncol Clin N Am       Date:  2019-08-02       Impact factor: 3.495

Review 6.  Current status of laparoscopic radical hilar cholangiocarcinoma in Mainland China.

Authors:  Yizhen Chen; Youyao Xu; Yuhua Zhang
Journal:  Biosci Trends       Date:  2020-05-09       Impact factor: 2.400

7.  Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments.

Authors:  Ilenia Bartolini; Matteo Risaliti; Laura Fortuna; Carlotta Agostini; Maria Novella Ringressi; Antonio Taddei; Paolo Muiesan
Journal:  Radiol Oncol       Date:  2020-07-29       Impact factor: 2.991

Review 8.  Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvant Strategies.

Authors:  E Una Cidon
Journal:  Clin Med Insights Oncol       Date:  2016-05-12

9.  Proposal of the optimal numbers of examined and positive lymph nodes to the 8th edition of American Joint Committee on Cancer (AJCC) staging for 758 patients with distal cholangiocarcinoma.

Authors:  RuiYang Wu; Gang Zhang; Jiao Feng; Liang Zhang; ZhiMing Yang
Journal:  PLoS One       Date:  2020-06-16       Impact factor: 3.240

10.  Comparison of the clinical results of surgical resection for extrahepatic cholangiocarcinomas: Hilar cholangiocarcinoma and mid-to-distal cholangiocarcinoma.

Authors:  Pyung Jung; Eung-Ho Cho; Sang-Bum Kim; Ryoung-Go Kim
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2019-11-29
View more
  1 in total

Review 1.  Progress and Current Limitations of Materials for Artificial Bile Duct Engineering.

Authors:  Qiqi Sun; Zefeng Shen; Xiao Liang; Yingxu He; Deling Kong; Adam C Midgley; Kai Wang
Journal:  Materials (Basel)       Date:  2021-12-06       Impact factor: 3.623

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.